Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Penthrox IND approved in China

Nov 21, 2019Mark EdwardsNews

21 November 2019

ASX ANNOUNCEMENT

Penthrox IND approved in China

Medical Developments International Limited (ASX: MVP) is delighted to announce the Chinese National Medical Product Administration (NMPA) has approved the opening of MVP’s Investigative New Drug (IND) application.  This application is a critical step and building block to having Penthrox approved for sale in China.

MVP’s submission in China is to have Penthrox approved for two separate indications.  The first is for Trauma Pain and the second for Procedural Pain.

For more information please click on the follow link – China approves Penthrox IND

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter